Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2323
Título : | Effect of EGb761 supplementation on the content of copper in mouse brain in an animal model of Parkinson's disease |
Creador: | Rojas, Patricia |
Nivel de acceso: | Open access |
Palabras clave : | 1-Metil-4-fenilpiridinio - ratones Encéfalo - metabolismo - ratones Cobre - metabolismo - ratones Ginkgo biloba Ratones Consanguíneos C57BL Enfermedad de Parkinson - quimioterapia - ratones Enfermedad de Parkinson - metabolismo - ratones Fitoterapia Extractos Vegetales - farmacologia - ratones Extractos Vegetales - uso terapéutico - ratones 1-Methyl-4-phenylpyridinium - mice Brain - metabolism - mice Copper - metabolism - mice Ginkgo biloba Mice, Inbred C57BL Parkinson Disease - drug therapy - mice Parkinson Disease - metabolism - mice Phytotherapy Plant Extracts - pharmacology - mice Plant Extracts -therapeutic use - mice Contenido de cobre, 1-metil-4-phenylpyridinium, Modelo animal de enfermedad de Parkinson, Extracto de Ginkgo biloba, Cuerpo estriado Copper content; 1-Methyl-4-phenylpyridinium; Animal model of Parkinson’s disease; Ginkgo biloba extract; Striatum |
Descripción : | Objective: EGb761 is a well-defined mixture of active compounds extracted from Ginkgo biloba leaves with neuroprotective effects in an animal model of Parkinson's disease induced by 1-methyl-4-phenylpyridinium (MPP+). Because copper has been implicated in Parkinson's disease, we investigated whether the protective effect of EGb761 in MPP+ neurotoxicity is related to the regulation of copper in the brain. Methods: C-57BL/6 mice were pretreated with EGb761 (10 mg/kg) daily for 17 d followed by administration of MPP+ (0.72 mg/kg); the mice were sacrificed 24 h later. The copper content of the striatum, midbrain, hippocampus, frontal cortex, and cerebellum was analyzed by graphite furnace atomic absorption spectrophotometry. Copper content is expressed as μg of copper per gram of wet tissue. Results: Copper content was reduced in the corpus striatum (45%; P < 0.05), and increased in the midbrain (65%; P < 0.05) and hippocampus (116%; P < 0.001) after MPP+ administration. EGb761 pretreatment of the MPP+ group prevented changes in the copper content of the striatum, midbrain, and hippocampus. No significant changes were found in the copper content of the cerebellum and frontal cortex in all treatment groups. Conclusion: We showed that the protective effect of EGb761 against MPP+ neurotoxicity may be due in part to the regulation of copper homeostasis in the brain. © 2009 Elsevier Inc. All rights reserved. |
Colaborador(es) u otros Autores: | Montes S Serrano-García N Rojas-Castañeda J |
Fecha de publicación : | 2009 |
Tipo de publicación: | Artículo |
Formato: | |
Identificador del Recurso : | 10.1016/j.nut.2008.10.013 |
Fuente: | Nutrition 25(4):482 - 485 |
URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2323 |
Idioma: | eng |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.